Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
Abstract Bispecific antibodies exhibit proven clinical benefit, and many bispecifics are currently in clinical development for oncology. Cytokine release syndrome (CRS) is a common clinical adverse effect observed following CD3‐based bispecific dosing. However, the pathophysiology of CRS is not full...
Main Author: | Jared Weddell |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12928 |
Similar Items
-
Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
by: Jared Weddell, et al.
Published: (2021-01-01) -
Recent advances of bispecific antibodies in solid tumors
by: Shengnan Yu, et al.
Published: (2017-09-01) -
625 Bispecific personalized aptamer for the treatment of solid tumors
by: Erez Lavi, et al.
Published: (2020-11-01) -
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022-11-01) -
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
by: Jim Middelburg, et al.
Published: (2021-01-01)